Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging of Brain Amyloid Plaques in the Aging Population

NCT00950430
Conditions
Alzheimer's Disease, Dementia With Lewy Bodies, Frontotemporal Dementia, Vascular Dementia
Interventions
Pittsburgh Compound B (C-11 PiB), F-18 FDG, Tau (18-F-AV-1451)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 100 Years
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Niemann-Pick Disease, Type C
Interventions
VTS-270
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 6 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Intracranial Aneurysm
Interventions
Embolization of intracranial aneurysm
Device
Lead sponsor
Tennessee Neurovascular Institute, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Lithium
Drug
Lead sponsor
Westat
Other
Eligibility
40 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 4 more
Conditions
Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions
AZ-3102, Placebo
Drug
Lead sponsor
Azafaros B.V.
Industry
Eligibility
4 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Therapy in Amyotrophic Lateral Sclerosis (TAME)

NCT02118727
Conditions
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Interventions
Memantine, Placebo (for Memantine)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • Jacksonville, Florida + 10 more
Completed Not applicable Interventional Results available

TMS for the Treatment of Primary Progressive Aphasia

NCT04188067
Conditions
Logopenic Variant Primary Progressive Aphasia, Non-fluent Variant Primary Progressive Aphasia, Semantic Variant Primary Progressive Aphasia
Interventions
Active rTMS, SHAM rTMS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Down Syndrome, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Michael Rafii
Other
Eligibility
30 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
La Jolla, California
Conditions
Niemann-Pick Disease, Type C1
Interventions
VTS-270
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Learning Amyloid and Tau Results

NCT07222930
Conditions
Alzheimer Disease
Interventions
Disclose amyloid, tau results, Follow-up Assessments
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
45 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Primary Progressive Aphasia, Behavioral Variant of Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Interventions
F-18 AV 1451
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
Interventions
Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
Procedure · Genetic
Lead sponsor
AviadoBio Ltd
Industry
Eligibility
30 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
3
States / cities
Columbus, Ohio • Nashville, Tennessee • Houston, Texas
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Music, Social Attention, and Dementia

NCT06768996
Conditions
Frontotemporal Dementia, Alzheimer Disease
Interventions
Synchronous Rhythm Production, Solo Rhythm Production
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Pick Disease of the Brain
Interventions
Direct Current Polarization
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Niemann-Pick Disease, Type C
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 120 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Niemann-Pick Disease, Type C
Interventions
Arimoclomol
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
2 Years and older
U.S. locations
13
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 10 more
Conditions
Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic, Traumatic Encephalopathy Syndrome, Nonfluent Aphasia, Progressive
Interventions
BIIB092, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 60 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Jersey City, New Jersey
Terminated Phase 2Phase 3 Interventional Results available

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT04958642
Conditions
Niemann-Pick Disease, Type C
Interventions
Adrabetadex
Drug
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 12 more
Conditions
Niemann-Pick Diseases
Interventions
Not listed
Lead sponsor
National Niemann-Pick Disease Foundation
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiovascular Disease, Cerebrovascular Disorders
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
10 Years and older
Enrollment
26,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Clearwater, Florida